Help oncology patients achieve better outcomes

Mika enables cancer patients to engage in proactive self-care and improve their health literacy. From side effect tracking to emotional support, Mika offers patients agency and relief, even on the toughest days.
Contact us to learn more

Committed to medical accuracy
Mika is developed in collaboration with leading oncology institutes like Charité Berlin, among many others, and our content is rigorously fact-checked by medical professionals.
Certified medical device
Mika’s digital therapeutic is a CE marked, certified medical device in accordance with Medical Device Regulation EU MDR 2017/745 Class IIa, ISO 13485, and ISO 27001 for data protection.
Proven efficacy
Mika has been proven to offer clinically-effective psycho-oncological treatment support that helps reduce symptoms of distress, anxiety, and fatigue in cancer patients.

How can Mika support your patients and practice?

In the clinic and doctor's office

Mika enables patients to easily track their symptoms and side effects. That means they can arrive at their consultations with documented evidence of their experience.
  • Get a quick, reliable overview of treatment progress
  • Make more informed decisions thanks to accurate data
  • Tailor treatment plans to specific patient needs

At home with patients

Mika offers patients evidence-based, guideline-compliant, validated psycho-oncological content designed to increase health literacy and reduce psychological distress. All our content is accessible and presented in layman’s terms.
  • Patients get reliable, easy-to-understand information
  • Patients are enabled to take active steps in their recovery
  • Practical tips proven to improve everyday wellbeing

We partner with leaders in cancer research


Healthcare professionals trust Mika

„Digital therapeutic support, as provided by the Mika app, represents a meaningful improvement in the care provided in oncology.“
Prof. Dr. Anja Mehnert-Teuerkauf
Department Head of Medical Psychology and Medical Sociology, Leipzig University Cancer Center
„I see the Mika cancer app as a very innovative add-on in the field of cancer patient education and information."
Prof. Dr. med. Dr. h.c. Jalid Sehouli
Director of Gynecology, Charité University Hospital
„The indispensable thing about the Mika app is that patients receive medically correct information. [...] Patients cannot get themselves 'lost' on the internet and cannot become victims of unfair business interests.“
Prof. Dr. med. Diana Lüftner
Member of the DGHO Board

Mika has been proven effective


Pilot study at Charité Berlin

A 12-week pilot study conducted at Charité Berlin looked at whether supporting cancer treatment with Mika had any effect. The patients who took part in the study had all been diagnosed with gynecological tumors.
Patients who used Mika reported a 23% reduction in feelings of fatigue and a 42% reduction in psychological distress after 12 weeks of using the app. This comparison was based on self-reported feelings in the 12-week period prior to using the app.
[1] Prospective Randomized Controlled Pilot Study of the Clinical Efficacy of the Fosanis Mika App 2020

Trial at University Hospital Leipzig

A randomized controlled trial (RCT) conducted at University Hospital Leipzig compared the effects of the Mika app on a group of patients over 12 weeks to a control group who did not use the app over the same period.
A number of distress-related parameters were assessed and found to be reduced in Mika app users:
  • Psychological distress
  • Symptoms of depression
  • Anxiety symptoms
  • Fatigue
This trial established that Mika is a clinically-effective psycho-oncological treatment support that can improve the mental health and wellbeing of cancer patients.

Partner trial at the NCT Heidelberg

A randomized controlled trial (RCT) at the National Center for Tumor Diseases in Heidelberg assessed the feasibility and efficacy of the SOFIA (Mika) smartphone app for early detection of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors.
During the 12-week trial, patients assigned to the intervention group used SOFIA to report twice weekly ePROs (electronic patient-reported outcomes) and receive cancer- and immunotherapy-relevant content.
SOFIA (Mika) showed high feasibility and acceptance and improved health-related quality of life and psychosocial outcomes.

Want to learn more?

Just add your details and we’ll get in touch. Prefer to email us directly? Simply drop us a line at
Form will go here.